Curis Posts Q4 Net Income $19.4M, Reveals 100% ORR in BTKi-Naïve PCNSL
Curis reported Q4 2025 net income of $19.4 million ($1.23 per share), reversing a $9.6 million loss a year earlier and narrowing its full-year loss to $7.6 million from $43.4 million. Emavusertib combination trials achieved 100% ORR in BTKi-naïve PCNSL, 37% in BTKi-experienced patients and 62.5% MRD conversions in AML.
1. Q4 Financial Highlights
Curis delivered a fourth-quarter net income of $19.4 million, or $1.23 per share, compared with a $9.6 million loss in Q4 2024. For full year 2025, the company posted a net loss of $7.6 million, or $0.58 per share, versus a $43.4 million loss a year earlier.
2. PCNSL and SCNSL Trial Results
In the TakeAim Lymphoma PCNSL study, emavusertib plus ibrutinib produced 100% objective response rate in five BTKi-naïve patients and 37% ORR in 19 BTKi-experienced patients, with median treatment duration of 123 days. In two SCNSL patients, the combination yielded one complete response and one stable disease with 38% tumor burden reduction.
3. AML MRD Conversion Data
An AML triplet study adding emavusertib to azacitidine and venetoclax showed 62.5% of eight MRD-positive patients converted to undetectable minimal residual disease across 7- and 14-day dosing cohorts, suggesting potential depth of response in frontline settings.
4. PIPE Financing Details
On January 9, 2026, Curis closed a private placement raising up to $80.8 million, including initial proceeds of $20.2 million and three warrant series exercisable at $0.75 per share. Series A, B and C warrants terminate in 2031, 30 days after fifth CLL dosing milestone, and 2027, respectively.